SCHEMBL22455486

SCHEMBL22455486

CCOC(=O)c1ccc(NC(=O)/C=C/c2cccc(C(=O)Nc3cccc(C(F)(F)F)c3)c2)nc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 7/20 0.53
▸ MEN1 O00255 6/20 0.53
▸ KMT2A Q03164 6/20 0.53
▸ LMNA P02545 3/20 0.53
▸ HSP90AA1 P07900 1/20 0.53
▸ PKM P14618 1/20 0.53
▸ NPSR1 Q6W5P4 1/20 0.53
▸ KIT P10721 2/20 0.51
▸ KDR P35968 2/20 0.51
▸ MAPK14 Q16539 2/20 0.51
▸ SMN1; SMN2 Q16637 3/20 0.49
▸ BRAF P15056 1/20 0.49
▸ RAB9A P51151 2/20 0.49
▸ MAPK1 P28482 2/20 0.49
▸ KDM4E B2RXH2 1/20 0.49
▸ NPC1 O15118 1/20 0.49
▸ ALDH1A1 P00352 1/20 0.49
▸ POLB P06746 1/20 0.49
▸ HTT P42858 2/20 0.48
▸ MAOB P27338 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22441687 0.88 MEN1 (0.59) MAPTMEN1KMT2ALMNAHSP90AA1
SCHEMBL22441690 0.88 MEN1 (0.59) MAPTMEN1KMT2ALMNAHSP90AA1
SCHEMBL22441632 0.88 MEN1 (0.62) MAPTMEN1KMT2ALMNAHSP90AA1
SCHEMBL22441633 0.88 MEN1 (0.62) MAPTMEN1KMT2ALMNAHSP90AA1
SCHEMBL22441675 0.84 MEN1 (0.59) MAPTMEN1KMT2ALMNAHSP90AA1
SCHEMBL22441674 0.84 MEN1 (0.59) MAPTMEN1KMT2ALMNAHSP90AA1
SCHEMBL22441820 0.82 MEN1 (0.54) MAPTMEN1KMT2ALMNAHSP90AA1
SCHEMBL22455325 0.82 MEN1 (0.54) MAPTMEN1KMT2ALMNAHSP90AA1
SCHEMBL22441752 0.82 MEN1 (0.56) MAPTMEN1KMT2ALMNAHSP90AA1
SCHEMBL22455053 0.82 MAPT (0.59) MAPTMEN1KMT2ALMNAHSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200299282-A1 COMPOUNDS AND METHODS FOR TREATING CANCER ANTIDOTE IP HOLDINGS LLC (US) 2020-09-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200299282-A1 COMPOUNDS AND METHODS FOR TREATING CANCER VHL, TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 MAPT 3913/4885MEN1 364/4885KMT2A 702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback